Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list
Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's weight loss and diabetes drugs Wegovy and Ozempic from its shortage list, a move that will sharply curtail the compounders' ability to sell cheaper versions of the drugs.
FDA says Ozempic, Wegovy are not in short supply anymore, which could impact prices
The U.S. Food and Drug Administration said Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply. CBS News New York reporter Ali Bauman reports on whether the supply change could lead to consumers paying more.
Delivery apps are allowing Chinese citizens to get their hands on the popular weight-loss and diabetes drugs at the touch of ...
People taking the weight-loss drug semaglutide could be at a slightly increased risk for a potentially blinding eye condition ...
The lawsuit claims the FDA's finding that there was no longer a shortage of the drugs' active ingredient semaglutide was ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback